Your browser doesn't support javascript.
loading
The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management.
Roberto, Michela; Panebianco, Martina; Aschelter, Anna Maria; Buccilli, Dorelsa; Cantisani, Carmen; Caponnetto, Salvatore; Cortesi, Enrico; d'Amuri, Sara; Fofi, Claudia; Ierinò, Debora; Maestrini, Viviana; Marchetti, Paolo; Marignani, Massimo; Stigliano, Antonio; Vivona, Luca; Santini, Daniele; Tomao, Silverio.
Afiliación
  • Roberto M; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit A, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • Panebianco M; Department of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Aschelter AM; Department of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Buccilli D; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit A, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • Cantisani C; Department of Dermatology, Complex Operative Unit (UOC) of Dermatology, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • Caponnetto S; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit B, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • Cortesi E; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit B, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • d'Amuri S; Department of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Fofi C; Department of Clinical and Molecular Medicine, Nephrology and Dialysis Unit, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Ierinò D; Department of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Maestrini V; Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Marchetti P; Scientific Direction, Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Rome, Italy.
  • Marignani M; Head Liver Disease Section, Digestive and Liver Diseases Department, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Stigliano A; Department of Clinical and Molecular Medicine, Endocrinology Unit, Sant 'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Vivona L; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit A, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
  • Santini D; Complex Operative Unit (UOC) Oncologia Medica, Sapienza University, Polo Pontino, Latina, Italy.
  • Tomao S; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Medical Oncology Unit A, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
Front Oncol ; 12: 1026978, 2022.
Article en En | MEDLINE | ID: mdl-36713496
The new landscape of treatments for metastatic clear cell renal carcinoma (mRCC) is constantly expanding, but it is associated with the emergence of novel toxicities, adding to up to those observed in the tyrosine-kinase inhibitor (TKI) era. Indeed, the introduction of immune checkpoint inhibitors (ICIs) alone or in combination has been associated with the development of immune-related adverse events (irAEs) involving multiple-organ systems which, even if rarely, had led to fatal outcomes. Moreover, due to the relatively recent addition of ICIs to the previously available treatments, the potential additive adverse effects of these combinations are still unknown. A prompt recognition and management of these toxicities currently represents a fundamental issue in oncology, since it correlates with the outcome of cancer patients. Even if clinical guidelines provide indications for the management of irAEs, no specific protocol to evaluate the individual risk of developing an adverse event during therapy is currently available. A multidisciplinary approach addressing appropriate interventions aimed at reducing the risk of any insidious, severe, and/or dose-limiting toxicity might represent the most efficacious strategy to timely prevent and manage severe irAEs, allowing indirectly to improve both patients' cancer-specific survival and quality of life. In this review, we reported a five-case series of toxicity events that occurred at our center during treatment for mRCC followed by the remarks of physicians from different specialties, pinpointing the relevant role of an integrated and extended multidisciplinary team in a modern model of mRCC patient management.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza